REFERENCES
- Lauffenburger M D, Cohen K L. Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis. Cornea. 1993; 12: 517–521, [PUBMED], [INFOTRIEVE], [CSA]
- Callegan M C, Engel L S, Hill J M, O'Callaghan R J. Ciprofloxacin versus tobramycin for the treatment of Staphylococcal keratitis. Invest Ophthalmol Vis Sci. 1994; 35: 1033–1037, [PUBMED], [INFOTRIEVE], [CSA]
- Moreau J M, Green L C, Engel L S, Hill J M, O'Callaghan R J. Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. Curr Eye Res. 1998; 17: 808–812, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Callegan M C, Hill J M, Insler M S, Hobden J A, O'Callaghan R J. Methicillin-resistant Staphylococcus aureus keratitis in the rabbit: therapy with ciprofloxacin, vancomycin and cefazolin. Curr Eye Res. 1992; 11: 1111–1119, [PUBMED], [INFOTRIEVE]
- O'Brien T P, Maguire M G, Fink N E, Alfonso E, McDonnell P. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol. 1995; 113: 1257–1265, [PUBMED], [INFOTRIEVE], [CSA]
- Hume E B, Moreau J M, Conerly L L, Cannon B M, Dajcs J J, Hill J M, O'Callaghan R J. Clarithromycin for experimental Staphylococcus aureus keratitis. Curr Eye Res. 1999; 18: 358–362, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gidley M J, Sanders J KM. Mechanisms of antibacterial formaldehyde delivery from noxythiolin and other ‘masked formaldehyde’ compounds. J Pharm Pharmacol. 1983; 35: 712–717, [PUBMED], [INFOTRIEVE]
- Gorman S P, McCafferty D F, Woolfson A D, Jones D S. Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with Taurolin, a novel antimicrobial agent. J Appl Bacteriol. 1987; 62: 315–320, [PUBMED], [INFOTRIEVE], [CSA]
- Brearley S, George R H. The rate of antibacterial action of noxythiolin and taurolin. J Hosp Infect. 1980; 1: 201–209, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Browne M K, Leslie G B, Pfirmann R W. Taurolin, a new chemotherapeutic agent. J Appl Bacteriol. 1976; 41: 363–368, [PUBMED], [INFOTRIEVE]
- http://www.geistlich.com/pharma/en/index.html, Geistlich Pharmaceuticals.-Taurolin profile. Available at: Accessed November 30, 2003
- Reinmuller J. Die Beeinflussung der physiologischen und pathologischen Gerinnung durch Taurolidin und Implikationen für die Anwendung [The influence of taurolidine on physiological and pathological blood coagulation and implications for its use]. Zentralbl Chir 1999; 124: 13–18, [PUBMED], [INFOTRIEVE]
- Jones D S, Gorman S P, McCafferty D F, Woolfson A D. The effects of three non-antibiotic, antimicrobial agents on the surface hydrophobicity of certain microorganisms evaluated by different methods. J Appl Bacteriol. 1991; 71: 218–227, [PUBMED], [INFOTRIEVE], [CSA]
- Bieselt R. Surgical therapy of pleural empyema with tauroline. Langenbecks Arch Chir. 1997; 382: 42–46
- Torres-Viera C, Thauvin-Eliopoulos C, Souli M, DeGirolami P, Farris M G, Wennersten C B, Sofia R D, Eliopoulos G M. Activities of taurolidine in vitro and in experimental enterococcal endocarditis. Antimicrob Agents Chemother. 2000; 44: 1720–1724, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Oguz H, Zeyrek F Y, Ozardali I, Oguz E, Gurkan T. Intravitreal taurolidine against experimental Staphylococcus epidermidis endophthalmitis in rabbits. Curr Eye Res. 2004; 28: 225–232, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Staubach K H. Adjuvant therapy of peritonitis with taurolidine. Modulation of mediator liberation. Langenbecks Arch Chir 1997; 382: S26–S30, [PUBMED], [INFOTRIEVE]
- Conlan A A, Abramor E, Delikaris P, Hurwitz S S. Taurolidine instillation as therapy for empyema thoracis. A prospective study of 50 patients. S Afr Med J. 1983; 64: 653–655, [PUBMED], [INFOTRIEVE]
- Marti M C, Moser G, Bordigoni P. Pleural empyema with Tauroflex. Study of a new bactericidal agent. Schweitz Med Wochenschr. 1978; 108: 215–216
- Zimmermann M, Preac-Mursic V. In vitro activity of taurolidine, chlorophenol-camphor-menthol and chlorhexidine against oral pathogenic microorganisms. Arzneimittelforschung. 1992; 42: 1157–1159, [PUBMED], [INFOTRIEVE]
- Schein O D, Ormerod L D, Barraquer E, Alfonso E, Egan K M, Paton B G, Kenyon K R. Microbiology of contact lens-related keratitis. Cornea. 1989; 8: 281–285, [PUBMED], [INFOTRIEVE]
- Wahl J C, Katz H R, Abrams D A. Infectious keratitis in Baltimore. Ann Ophthalmol. 1991; 23: 234–237, [PUBMED], [INFOTRIEVE]
- Limberg M B. A review of bacterial keratitis and bacterial conjunctivitis. Am J Ophthalmol. 1991; 112: 2S–9S, (4 Suppl)[PUBMED], [INFOTRIEVE]
- Callegan M C, Hobden J A, Hill J M, Insler M S, O'Callaghan R J. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. Invest Ophthalmol Vis Sci. 1992; 33: 3017–3023, [PUBMED], [INFOTRIEVE]
- Sloop G D, Moreau J M, Conerly L L, Dajcs J J, O'Callaghan R J. Acute inflammation of the eyelid and cornea in Staphylococcus keratitis in the rabbit. Invest Ophthalmol Vis Sci. 1999; 40: 385–391, [PUBMED], [INFOTRIEVE], [CSA]
- Blenkharn J I. In-vitro antibacterial activity of noxythiolin and taurolidine. J Pharm Pharmacol. 1990; 42: 589–590, [PUBMED], [INFOTRIEVE]
- Traub W H, Leonhard B, Bauer D. Taurolidine: in vitro activity against multiple-antibiotic-resistant, nosocomially significant clinical isolates of Staphylococcus aureus, Enterococcus faecium, and diverse Enterobacteriaceae. Chemotherapy 1993; 39: 322–330, [PUBMED], [INFOTRIEVE], [CSA]
- O'Callaghan R J, Callegan M C, Moreau J M, Green L C, Foster T J, Hartford O M, Engel L S, Hill J M. Specific roles of alpha-toxin and beta toxin during Staphylococcus aureus corneal infection. Infect Immunol. 1997; 65: 1571–1578, [CSA]
- Callegan M C, O'Callaghan R J, Hill J M. Pharmacokinetic considerations in the treatment of bacterial keratitis. Clin Pharmacokinet. 1994; 27: 129–149, [PUBMED], [INFOTRIEVE], [CSA]
- Engel L S, Callegan M C, Hill J M, Folkens A T, Shimomura Y, O'Callaghan R J. The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. Jpn J Ophthalmol. 1996; 40: 212–219, [PUBMED], [INFOTRIEVE], [CSA]
- Leibowitz H M. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol. 1991; 112: 34S–47S, [PUBMED], [INFOTRIEVE]
- Insler M S, Fish L A, Silbernagel J, Hobden J A, O'Callaghan R J, Hill J M. Successful treatment of methicillin-resistant Staphylococcus aureus keratitis with topical ciprofloxacin. Ophthalmology. 1991; 98: 1690–1692, [PUBMED], [INFOTRIEVE]
- Pollock G A, McKelvie P A, McCarty D J, White J F, Mallari P LT, Taylor H R. In vivo effects of fluoroquinolones on rabbit corneas. Clin Experiment Ophthalmol. 2003; 31: 517–521, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wilhelmus K R, Abshire R L. Corneal ciprofloxacin precipitation during bacterial keratitis. Am J Ophthalmol. 2003; 136: 1032–1037, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mallari P L, McCarty D J, Daniell M, Taylor H. Increased incidence of corneal perforation after topical fluoroquinolone treatment for microbial keratitis. Am J Ophthalmol. 2001; 131: 131–133, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Matsumoto S, Stern M E. Effect of anti-infective ophthalmic solutions on corneal cells in vitro. Adv Ther. 2000; 17: 148–151, [PUBMED], [INFOTRIEVE], [CSA]
- Kanski J J. Clinical OphthalmologyFourth edition. Butterworth-Heinemann, Oxford 1999; 105
- Reim M, Kottek A, Schrage N. The cornea surface and wound healing. Prog Retin Eye Res. 1997; 16: 183–225, [CROSSREF]
- Gorman S P, McCafferty D F, Woolfson A D, Jones D S. A comparative study of the microbial antiadherence capacities of three antimicrobial agents. J Clin Pharm Ther. 1987; 12: 393–399, [PUBMED], [INFOTRIEVE]
- Blenkharn J I. Sustained anti-adherence activity of taurolidine (Taurolin) and noxythiolin (Noxyflex S) solutions. J Pharm Pharmacol. 1988; 40: 509–511, [PUBMED], [INFOTRIEVE]
- Monson J R, Ramsey P S, Donohue J H. Taurolidine inhibits tumour necrosis factor (TNF) toxicity-new evidence of TNF and endotoxin synergy. Eur J Surg Oncol. 1993; 19: 226–231, [PUBMED], [INFOTRIEVE]
- Konukoglu D, Iynem H, Ziylan E. Antioxidant status in experimental peritonitis: effects of alpha tocopherol and taurolin. Pharmacol Res. 1999; 39: 247–251, [PUBMED], [INFOTRIEVE], [CROSSREF]